Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Adoptive Transfer of Chimeric Antigen Receptor (CAR) Engineered T cells for the Treatment of Metastatic Breast Cancer

FY 2011-12

Summary
Metastastic breast cancer poses a major clinical challenge, with the median survival of patients being approximately 2-3 years. The burgeoning field of cancer immunotherapy aims to harness the ability of immune cells to circulate throughout the body and destroy deposits of metastatic tumor cells. Successful immunotherapy would also be expected to yield "memory" cells that would persist and prevent tumor recurrence. T lymphocytes (aka T cells) are particularly effective at destroying tumors; however, naturally occurring tumor-specific T lymphocytes are rare. However, chimeric antigen receptors (CARs) can be engineered for expression on the surface of a T cell, which provide this tumor specificity. The CAR induces T cell activation signals and tumor killing upon interaction with its specific antigen, while sparing healthy tissue. We aim to investigate whether CAR transduced T cells can be used to treat metastatic breast cancer. Our studies will use a CAR specific to a model breast cancer antigen, HER2, which is commonly overexpressed on breast cancer cells. Bioluminescent imaging, qRT-PCR, histology, and multi-parameter flow cytometry are some of the techniques we will use to characterize the behaviour of CAR-engineered T cells in the tumor microenvironment while monitoring effects on tumor regression.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
253341
Name
Hammill Joanne A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Adoptive Transfer of Chimeric Antigen Receptor (CAR) Engineered T cells for the Treatment of Metastatic Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Transfer; Bioluminescent Imaging; Cancer Immunotherapy; Chimeric Antigen Receptor; Immune Regulation; Lymphocyte Biology; Metastatic Breast Cancer; Murine Models; T Cells; Tumor Immunity
Abstract
Metastastic breast cancer poses a major clinical challenge, with the median survival of patients being approximately 2-3 years. The burgeoning field of cancer immunotherapy aims to harness the ability of immune cells to circulate throughout the body and destroy deposits of metastatic tumor cells. Successful immunotherapy would also be expected to yield "memory" cells that would persist and prevent tumor recurrence. T lymphocytes (aka T cells) are particularly effective at destroying tumors; however, naturally occurring tumor-specific T lymphocytes are rare. However, chimeric antigen receptors (CARs) can be engineered for expression on the surface of a T cell, which provide this tumor specificity. The CAR induces T cell activation signals and tumor killing upon interaction with its specific antigen, while sparing healthy tissue. We aim to investigate whether CAR transduced T cells can be used to treat metastatic breast cancer. Our studies will use a CAR specific to a model breast cancer antigen, HER2, which is commonly overexpressed on breast cancer cells. Bioluminescent imaging, qRT-PCR, histology, and multi-parameter flow cytometry are some of the techniques we will use to characterize the behaviour of CAR-engineered T cells in the tumor microenvironment while monitoring effects on tumor regression.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hammill, Joanne A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~